Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities.

Asia-Pacific journal of clinical oncology - 1 Feb 2018

Aw Derrick Chen-Wee, Tan Eng Huat, Chin Tan Min, Lim Hong Liang, Lee Haur Yueh, Soo Ross A

Abstract excerpt

Patients with advanced stage non-small cell lung cancer with sensitizing epidermal growth factor receptor (EGFR) mutations using EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib and afatinib as first-line treatment had better progression-free survival, overall response rate and quality of life than those on chemotherapy. Although EGFR TKIs are commonly associated with skin-related (rash,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diarrhea

Share to Disease-Free Survival

Share to Drug Eruptions

Share to ErbB Receptors

Share to Protein Kinase Inhibitors

Share to Quality of Life

Source

Identifiers

PMID: 28464435
DOI: 10.1111/ajco.12687

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities.PMID 28464435Read ↗

A review on adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in nonsmall cell lung cancer patients.Semantic proximity Read ↗

Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK.Semantic proximity Read ↗

Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.Semantic proximity Read ↗

Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer.Semantic proximity Read ↗

Association between dermatologic adverse events and quality of life in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors.Semantic proximity Read ↗

Safety of gefitinib in non-small cell lung cancer treatment.Semantic proximity Read ↗

Drug-induced Hypersensitivity Syndrome by EGFR-TKI in a Patient with Lung Cancer.Semantic proximity Read ↗

[Toxicity associated with EGRF inhibition: review and key aspects in the management of afatinib].Semantic proximity Read ↗

Successful erlotinib rechallenge in an EGFR-mutant metastatic non-small cell lung cancer patient with afatinib-induced drug rash with eosinophilia and systemic symptoms: A case report.Semantic proximity Read ↗

Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer.Semantic proximity Read ↗

[Efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy as first-line treatment for epidermal growth factor receptor-mutant advanced non-small cell lung cancer].Semantic proximity Read ↗

Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.